Thyroid Antibodies TPO & TgAb: What Your Results Mean

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional about your results.

Most thyroid conversations start and end with TSH. But TSH measures the pituitary's signal to the thyroid, not whether the thyroid itself is under immunological attack. That distinction matters enormously. You can have a perfectly normal TSH, a normal Free T4, and a normal Free T3 while your immune system is quietly destroying thyroid tissue through an antibody-mediated process that will, over years, progressively reduce function. The test that reveals that process is a thyroid antibody panel.

This guide covers the three antibodies tested in autoimmune thyroid disease: thyroid peroxidase antibody (TPO Ab), thyroglobulin antibody (TgAb), and TSH receptor antibody (TRAb). It explains what each measures, how to distinguish Hashimoto's from Graves' disease on paper, what elevated antibodies with a still-normal TSH actually mean prognostically, and how monitoring is approached in the Australian testing context.

What thyroid antibodies are measuring

The immune system normally ignores the body's own tissues. In autoimmune thyroid disease, that tolerance breaks down and the immune system produces antibodies that target thyroid-specific proteins. These antibodies do not simply mark the thyroid as foreign, they interfere directly with thyroid function, trigger complement-mediated destruction, or in the case of TRAb, bind to and activate the TSH receptor itself.

Three proteins are the primary targets:

• Thyroid peroxidase (TPO): The enzyme responsible for iodinating thyroglobulin during thyroid hormone synthesis. Anti-TPO antibodies interfere with this process and also attract complement and natural killer cells, causing progressive follicular destruction.
• Thyroglobulin (Tg): The protein scaffold on which thyroid hormones are assembled and stored inside follicles. Anti-Tg antibodies (TgAb) are less directly destructive than TPO Ab but are a reliable marker of autoimmune activity.
• TSH receptor (TSHR): The receptor on thyroid follicular cells that responds to pituitary TSH. TRAb (also called TSH receptor antibodies, or when functionally characterised, thyroid-stimulating immunoglobulins/TSI) bind this receptor and either stimulate it continuously, driving hyperthyroidism in Graves' disease, or block it, contributing to hypothyroidism.

TPO antibodies: the core Hashimoto's marker

TPO antibodies are elevated in over 90% of people with Hashimoto's thyroiditis and in approximately 70–80% of people with Graves' disease. They are the most sensitive single antibody for detecting autoimmune thyroid disease and the one most predictive of long-term thyroid failure.

What counts as elevated?

Australian laboratory reference ranges for TPO Ab typically use a cut-off of <35 IU/mL or <60 IU/mL depending on the assay platform. Values between the assay cut-off and approximately 100 IU/mL are frequently described as "borderline" in reports, though clinically they carry the same directional significance as clearly elevated values: ongoing autoimmune activity is present.

Functional medicine practitioners often treat any result above 35 IU/mL as clinically meaningful, particularly when it is rising serially or when the patient has symptoms consistent with early Hashimoto's. The absolute titre does not map cleanly to symptom severity, but higher titres, particularly above 500 IU/mL, are associated with more aggressive tissue destruction and a more volatile TSH pattern over time.

The progression risk

A large population-based cohort study (the Tehran Thyroid Study) followed over 5,000 participants for a median of 9.1 years and found that TPO Ab positivity predicted progression to overt hypothyroidism at approximately 4.3% per year, compared with 2.6% per year in antibody-negative individuals. The risk compounded substantially when mildly elevated TSH was present alongside positive antibodies. Over a 20-year horizon, the combination of elevated TSH and elevated TPO Ab carried an odds ratio of 38 (95% CI 22–65) for developing overt hypothyroidism.¹

This is the core reason a positive TPO Ab result with a currently normal TSH is not "just a finding." It is a forecast with quantified annual risk.

TgAb: the second autoimmune signal

Thyroglobulin antibodies are positive in 50–80% of Hashimoto's cases, making them less sensitive than TPO Ab for initial screening. They are, however, independently useful in two situations.

First, approximately 5–10% of people with Hashimoto's are TPO Ab-negative but TgAb-positive. Testing both antibodies avoids missing this subgroup. Second, TgAb is the primary assay used in thyroid cancer surveillance: because serum thyroglobulin is the tumour marker used post-thyroidectomy to detect recurrence, TgAb can interfere with accurate Tg measurement (causing false-low results), so labs must report both together to flag whether the Tg value is reliable.

In an autoimmune thyroid disease context, TgAb elevation without TPO Ab elevation is generally a weaker signal, but it still warrants periodic monitoring of TSH and Free T4, particularly if symptoms are present.

TgAb can also be transiently elevated following viral thyroiditis (de Quervain's thyroiditis), where it resolves once the acute phase passes. This is distinct from the persistent elevation seen in Hashimoto's.

TRAb: the Graves' disease marker

TSH receptor antibodies are the diagnostic marker for Graves' disease. They are positive in approximately 95% of active Graves' cases. Their mechanism is fundamentally different from TPO Ab and TgAb: rather than causing tissue destruction, TRAb (specifically the stimulating subtype, TSI) bind the TSH receptor and activate it continuously, bypassing pituitary regulation entirely. The result is unrelenting stimulation of thyroid hormone synthesis independent of feedback.

Stimulating vs blocking TRAb

TRAb assays measure total antibody binding to the TSH receptor. Some laboratories and specialists further characterise whether the antibodies are stimulating (TSI) or blocking (TBIAb). Stimulating TRAb drives hyperthyroidism; blocking TRAb can cause hypothyroidism despite a "positive" TRAb result. Most routine TRAb assays in Australia report a single value reflecting receptor-binding activity without distinguishing stimulating from blocking forms, which is adequate for initial diagnosis but relevant if the clinical picture is ambiguous.

A 2024 review in Frontiers in Endocrinology confirmed that thyroid-stimulating immunoglobulin (TSI) and TRAb are highly correlated at diagnosis, and both track disease activity during antithyroid drug treatment, making serial TRAb monitoring a validated tool for predicting Graves' remission likelihood.²

TRAb in Hashimoto's patients

TRAb is occasionally weakly positive in Hashimoto's patients, particularly during an acute flare. This does not mean Graves' disease is developing; the antibody titre in Hashimoto's is typically far lower than in active Graves', and the clinical picture (hypothyroid symptoms, elevated TSH) is usually the opposite of what TRAb-driven Graves' would produce.

Distinguishing Hashimoto's from Graves' on paper

Both diseases produce elevated thyroid antibodies and both are autoimmune, but their antibody signatures, TSH trends, and clinical directions differ:

In practice, the combination of high TPO Ab + rising TSH + hypothyroid symptoms = Hashimoto's. High TRAb + suppressed TSH + hyperthyroid symptoms = Graves'. Overlap states (Hashitoxicosis, transient hyperthyroidism during early Hashimoto's) do exist and can confuse the picture, but they are self-limiting.

Elevated antibodies with a normal TSH: what it means

This is the most clinically underappreciated scenario. A person has elevated TPO Ab (or TgAb), a completely normal TSH, say 1.6 mIU/L, and is told their thyroid is fine. From a standard care perspective, this is technically accurate: thyroid function is currently normal. But from a prognostic perspective, something important is being missed.

A 2017 review in Frontiers in Immunology by Fröhlich and Wahl summarised evidence across multiple population cohorts: thyroid autoantibodies are detected in subjects without manifest thyroid dysfunction, but their presence predicts future dysfunction and is also associated with extra-thyroidal phenomena including effects on mood, fertility, and pregnancy outcomes.³

Key clinical implications of antibody-positive, euthyroid status:

TSH should be re-checked annually at minimum. Given a ~4% annual conversion rate to overt hypothyroidism, "normal now" does not mean "normal in five years." Annual monitoring catches early TSH drift before symptoms develop.

TSH alone may look normal while Free T3 is declining. In early Hashimoto's, the gland compensates via upregulated conversion and increased TSH drive, both of which can maintain normal Free T4 and Free T3 at TSH values still within reference range. For a fuller picture of how Free T3, Free T4, and reverse T3 interact during this compensatory phase, see the complete thyroid panel guide.

Antibody titre can be tracked. While there is no treatment indicated solely for antibody positivity in a euthyroid patient within standard care, some practitioners monitor titre trajectory as a proxy for disease activity. A titre that doubles in 12 months is a different clinical situation from one that has been stable at 80 IU/mL for three years.

Subclinical hypothyroidism + positive TPO Ab = treat threshold lowers. Australian endocrinology guidelines (consistent with American Thyroid Association guidance) suggest that a TSH between 4.5 and 10 mIU/L warrants more serious consideration of levothyroxine treatment when TPO Ab is also positive, because the annual risk of progression is substantially higher.

Australian testing context

Medicare covers a TPO Ab test when ordered alongside a thyroid function test in specific clinical circumstances (suspected autoimmune thyroid disease, monitoring). TgAb and TRAb are covered in defined indications, TRAb in suspected or known Graves' disease; TgAb when thyroglobulin monitoring is indicated.

Private blood testing providers (Laverty, Sullivan Nicolaides, via self-referral services) typically offer full thyroid antibody panels without requiring a GP referral. A full autoimmune thyroid panel includes: TSH, Free T4, Free T3, TPO Ab, TgAb, and optionally TRAb if hyperthyroidism is suspected. Costs via private request typically range from $60–$120 depending on what is bundled.

Reference ranges vary by laboratory platform (immunoassay method, calibrator source). It is worth noting the platform when comparing serial results, a jump from 80 to 130 IU/mL is more meaningful if it occurred on the same platform.

For detail on what to do with the broader thyroid panel (including how TSH optimal ranges differ from reference ranges, and how Free T3:Free T4 ratio is interpreted) the reverse T3 and thyroid function article covers peripheral conversion in depth.

Monitoring frequency and what to watch

For someone with positive TPO Ab and a currently normal thyroid panel, a reasonable monitoring protocol is:

• TSH + Free T4 annually
• Full panel (adding Free T3, TPO Ab titre) every 1–2 years or sooner if symptoms develop
• TRAb only if symptoms of hyperthyroidism emerge

If TSH begins to rise above 2.5 mIU/L on serial tests, this warrants a closer look, not because 2.5 is pathological, but because the trajectory in the context of positive antibodies matters. A TSH of 2.5 rising to 3.2 to 4.1 over three years is a different clinical story from the same three values in a random order.

People with Graves' disease in remission (antibody-positive, now euthyroid on reduced or no medication) should have TRAb monitored every 6–12 months during the first two years post-treatment, as titre decline is the most reliable predictor of sustained remission versus relapse.

For anyone building a picture of their thyroid health over time, understanding how all the panel components fit together is essential. The how to interpret blood test results guide explains how to track changes across visits in a clinically meaningful way.

Key takeaways

Thyroid antibody testing adds a dimension to thyroid assessment that TSH alone cannot provide. TPO Ab is the primary marker for Hashimoto's autoimmune thyroiditis and carries a quantified annual risk of progression to overt hypothyroidism even when current function is normal. TgAb is a secondary autoimmune signal that captures cases TPO Ab misses and is essential for accurate thyroglobulin tumour marker interpretation. TRAb is the Graves' disease marker: its presence with suppressed TSH and hyperthyroid symptoms confirms the diagnosis; its titre tracks treatment response and remission probability.

Elevated antibodies with a normal TSH is not a reason for reassurance, it is a reason for annual monitoring, lifestyle consideration (selenium, vitamin D, stress management), and awareness of the prognostic implications. The thyroid panel and the antibody panel are best read together, as parts of the same autoimmune trajectory.